Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
FTRE
Fortrea Holdings Inc.
Fortrea operates as a standalone contract research organization providing outsourced clinical development services.
|
$1.14B |
$12.91
+8.03%
|
|
MBX
MBX Biosciences, Inc. Common Stock
MBX's lead programs are peptide-based therapeutics delivered via a proprietary long-acting Precision Endocrine Peptide (PEP™) platform, i.e., Peptide Therapeutics.
|
$1.14B |
$33.86
+7.15%
|
|
NVAX
Novavax, Inc.
Novavax develops, manufactures, and commercializes vaccines (e.g., Nuvaxovid), placing it squarely in the vaccines product category.
|
$1.13B |
$6.95
+3.89%
|
|
USPH
U.S. Physical Therapy, Inc.
Directly operates outpatient physical therapy clinics and ambulatory care services.
|
$1.12B |
$74.34
+0.25%
|
|
PGEN
Precigen, Inc.
Direct platform and lead asset are gene therapy products, making Biotech - Gene Therapy a core tag.
|
$1.11B |
$3.75
+2.18%
|
|
PVLA
Palvella Therapeutics, Inc.
Palvella Therapeutics concentrates on rare genetic skin diseases and markets a proprietary topical rapamycin platform (QTORIN), indicating a core focus on rare disease biotech development.
|
$1.11B |
$99.68
+5.07%
|
|
IMTX
Immatics N.V.
Core product platform: TCR-engineered cell therapies (ACT) for solid tumors.
|
$1.09B |
$10.59
-3.46%
|
|
THRM
Gentherm Incorporated
Medical devices & biometrics including patient temperature management devices.
|
$1.09B |
$35.67
-1.08%
|
|
ABCL
AbCellera Biologics Inc.
AbCellera's primary product is its antibody discovery platform.
|
$1.09B |
$3.63
+0.41%
|
|
INMD
InMode Ltd.
InMode's core business is medical devices and biometrics, with RF-based aesthetic platforms and related systems.
|
$1.08B |
$14.06
-0.50%
|
|
PHAT
Phathom Pharmaceuticals, Inc.
VOQUEZNA (vonoprazan) is an oral small-molecule therapeutic (P-CAB) with GERD and H. pylori indications, representing the company’s core product line.
|
$1.08B |
$15.18
+1.67%
|
|
RAPP
Rapport Therapeutics, Inc. Common Stock
Lead asset RAP-219 is a small molecule AMPAR NAM targeting neuronal ion channels, i.e., ion channel modulators.
|
$1.07B |
$29.41
+2.90%
|
|
PCRX
Pacira BioSciences, Inc.
Pacira's pMVL-based Drug Delivery Platforms enable extended-release formulations used in EXPAREL and ZILRETTA.
|
$1.07B |
$23.82
+2.78%
|
|
OPK
OPKO Health, Inc.
OPKO's BioReference segment provides laboratory testing and advisory services.
|
$1.06B |
$1.35
|
|
KURA
Kura Oncology, Inc.
Kura's core business is oncology-focused biotechnology developing ziftomenib and related menin inhibitors for AML, placing it in Biotech - Oncology.
|
$1.04B |
$11.98
+3.28%
|
|
BCAX
Bicara Therapeutics Inc. Common Stock
Directly focused on oncology therapeutics; Bicara's lead candidate is an antibody-based cancer therapy.
|
$1.04B |
$18.97
+2.76%
|
|
IART
Integra LifeSciences Holdings Corporation
Wound care/regenerative product portfolio (IDRT, PriMatrix, SurgiMend, DuraSorb, MediHoney) constitutes major product lines.
|
$1.02B |
$13.11
-1.06%
|
|
EYPT
EyePoint Pharmaceuticals, Inc.
Lead asset is an ophthalmic drug (DURAVYU) targeting wet AMD and DME.
|
$1.02B |
$14.78
+0.24%
|
|
MDXG
MiMedx Group, Inc.
Directly manufactures and sells wound care devices and placental tissue allografts (EPIFIX, EPICORD, EPIEFFECT) used in wound healing.
|
$1.02B |
$6.89
-0.86%
|
|
TBPH
Theravance Biopharma, Inc.
Ampreloxetine is an oral small-molecule therapeutic in Phase 3 (CYPRESS) for symptomatic nOH in MSA, representing a core TBPH pipeline asset.
|
$1.01B |
$19.97
+5.44%
|
|
BHVN
Biohaven Ltd.
BHVN's Kv7 ion channel modulation platform (BHV-7000) and TRPM3 antagonist (BHV-2100) position the company in Ion Channel Modulators, a key neuroscience/pain modality.
|
$1.00B |
$9.51
+1.06%
|
|
VERV
Verve Therapeutics, Inc.
Verve Therapeutics' core offering is in vivo gene therapy using base editing delivered to liver cells, aligning with Biotech - Gene Therapy.
|
$988.30M |
$11.13
|
|
GLUE
Monte Rosa Therapeutics, Inc.
GLUE develops oral small-molecule molecular glue degraders (MGDs) as its core therapeutic modality.
|
$987.53M |
$15.97
-0.28%
|
|
PNTG
The Pennant Group, Inc.
Pennant's direct service offerings include Home Health and Hospice care across the post-acute continuum.
|
$970.85M |
$28.09
+0.07%
|
|
NBTX
Nanobiotix S.A.
NBTXR3 is Nanobiotix's lead oncology therapy (hafnium oxide nanoparticle) used to enhance radiation therapy, fitting Biotech - Oncology.
|
$966.56M |
$20.20
-4.85%
|
|
DAWN
Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals markets and develops Oral Small Molecule Therapeutics (OJEMDA/tovorafenib) as a lead product.
|
$963.88M |
$9.42
-0.11%
|
|
SANA
Sana Biotechnology, Inc.
Sana's lead platform is HIP-modified cell therapy (ex vivo) for allogeneic cell transplantation.
|
$955.98M |
$4.03
+14.81%
|
Showing page 14 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
